CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 1,650 target
Drug / intervention
Entire supraclavicular lymph node radiotherapy +1 moreradiation
Likely dose
Not stated in record
Key inclusion· 9
  • ECOG performance status 0-1
  • Newly diagnosed invasive breast cancer
  • Stage requirement: T1-4 N0-3a/b M0 initially; if no neoadjuvant chemo then pathological stage T1-3 N2-3a/b M0; if neoadjuvant chemo then clinical stage III or pathological T1-4 N1-3a/b M0
  • Breast conservative surgery or mastectomy with clear negative margins
Key exclusion· 13
  • Initial clinical diagnosis N3c (supraclavicular node metastasis)
  • T4 or inflammatory breast cancer with inadequate response to neoadjuvant chemotherapy
  • Distant metastasis
  • Bilateral breast cancer or previous contralateral breast cancer

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05059379
NCT05059379Phase 3RecruitingOn TrackUpdated 56mo ago
Long Recruiting

A Multicenter Randomized Controlled Phase III Study of Medial vs. Entire Supraclavicualr Lymph Node Radiation Therapy for Patients With Pathologically Positive Axillary Lymph Node and High Risk of Recurrence After Breast Cancer Surgery

Fudan University·interventional·Posted Sep 28, 2021·Updated Oct 25, 2021

In Brief

A Phase 3 clinical trial evaluating Entire supraclavicular lymph node radiotherapy and Medial supraclavicular lymph node radiotherapy for Breast Cancer and 2 related conditions. Currently recruiting, targeting 1,650 participants across 1 site.

Detailed Summary

Locally advanced breast cancer has high-risk local regional recurrence after surgery. Radiotherapy could reduce the local regional recurrence and improve disease free survival and overall survival. Regional lymph node irradiation is the important part of breast cancer radiotherapy. However, there are some controversies about regional lymph node delineation, especially the supraclavicular irradiation volume. Many studies had confirmed that posterolateral region of the supraclavicular fossa (also named Posterior neck lymph node) had a high risk involvement based on the mapping of recurrence nodes. This randomized phase III trial compares medial supraclavicular lymph node irradiation with entire supraclavicular lymph node irradiation in patients with pathologically positive axillary lymph node and high risk of recurrence after mastectomy or breast conservative surgery. It is not yet known if radiation works better with entire supraclavicular fossa than medial supraclavicular fossa.

Study Details

Timeline

Phase 3Recruiting
202220232024202520262027
First PostedSep 28, 2021
Enrollment StartSep 20, 2021
Primary CompletionAug 1, 2026
Study CompletionAug 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 4.8 years agoPrimary completion in 29 days

Interventions

Entire supraclavicular lymph node radiotherapyradiation

Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node. Entire supraclavicular lymph node includes medial supraclavicular and posterior neck lymph node.

Medial supraclavicular lymph node radiotherapyradiation

Radiation is delivered to the breast/chest wall, undissected axilla, internal mammary nodes and entire supraclavicular lymph node.